^
Association details:
| Biomarker: | YBX1 rs10493112 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients
Published date:
08/13/2020
Excerpt:
In abiraterone-treated and high-risk patients, YB-1 rs10493112 AA genotype carriers showed lower progression-free survival than C allele genotype patients (4 vs 17 months; p = 0.009). For carriers of AA genotype, multivariate Cox regression analysis revealed a fivefold increased risk of progression (p = 0.035).
DOI:
10.2217/pgs-2020-0008
